According to early research, not-yet-approved RT002 (DaxibotulinumtoxinA for Injection, Revance Therapeutics) lasts longer, might be safer and offers more dramatic wrinkle reduction than today’s most popular neurotoxin Botox (Allergan).
As the neurotoxin market is set for expansion, so expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeits.
Kent Remington, M.D., guides patients through his method for conducting a successful aesthetic consult, he told attendees at the MauiDerm 2014 meeting. Knowing a patient’s “real” reasons for aesthetic improvement — and shifting from a monotherapy toward performing a full-face rejuvenation following a multitherapeutic approach — are essential in achieving excellent aesthetic outcomes, he told attendees at the MauiDerm 2014 meeting.
Joel Cohen, M.D., explained to attendees at MauiDerm 2014 the differences among the three approved botulinum toxin products and how to use them successfully to take advantage of their unique properties. He recommended that doctors really think about these products as unique and begin to use them for their individual properties.
We now have three neurotoxins in our marketplace. Do you feel that these neurotoxins differ, and if so, how? An expert panel addresses the topic at the 2013 Vegas Cosmetic Surgery and Aesthetic Dermatology meeting.
Lateral canthal rhytids treated with three injections of abobotulinumtoxinA (Dysport, Medicis) showed no statistically significant difference from those treated with one injection, according to a study in the August issue of the Journal of Drugs in Dermatology.